Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

GSK pursuing split as easing of COVID curbs aids earnings

Stock MarketsApr 28, 2021 08:35AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility 2/2

By Pushkala Aripaka and Ludwig Burger

(Reuters) -Plans for GlaxoSmithKline (NYSE:GSK) to split in two are "well underway" it said on Wednesday after exceeding first-quarter earnings forecasts as an easing of COVID-19 curbs meant more clinic visits for critical treatments such as HIV and routine shots.

GSK has fallen behind in the coronavirus vaccines race and its broader strategy has been under the microscope after a report that U.S. activist investor Elliott built up a significant stake.

The British drugmaker said it would provide details on June 23 on its plan to separate next year into an over-the-counter products business and another for prescription medicines and vaccines.

Chief Executive Emma Walmsley said she was focused on GSK's broader transformation and delivering shareholder value.

The separation was spearheaded by Walmsley, a former head of GSK's consumer business, to simplify operations.

Walmsley took the top job in 2017 despite some investor pressure to name an outsider as CEO and such calls may grow with Elliott's arrival on the register.

"With major structural change on the cards at GSK, with or without Elliott’s alternative vision, it looks set to be a year of forced evolution at GSK," Steve Clayton, manager of Hargreaves Lansdown (LON:HRGV)'s Select UK Income Shares fund, said in a note.

GSK said that turnover for the three months to March fell 15% to 7.42 billion pounds ($10.28 billion) at constant currency rates, while adjusted earnings stood at 22.9 pence per share, down by a third.

Analysts had expected adjusted earnings of 21.9 pence per share and sales of 7.83 billion pounds, a company-compiled consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus of 17 analysts showed.

Walmsley launched GSK's split, which involves merging its over-the-counter products business into a venture with Pfizer (NYSE:PFE) and separating this from its prescription medicines and vaccines units, last year.

Investments to prepare for the division have hurt earnings, but GSK hopes the streamlined operations resulting from it will pay off in the long term.

Walmsley said that while GSK's consumer health business had great prospects and a "fantastic" leadership team, she would seek to remain in control of the bigger picture.

"I’m very focused on leading GSK through that successful separation and beyond," Walmsley told a results briefing, adding that she saw her role as CEO as setting the strategy, hiring top people and allocating capital, while leaving the medical science to the experts.

"I've clearly laid out from day one ... and included in that has been the best possible R&D leadership in the world," Walmsley said in response to suggestions that her lack of scientific background meant she would be better suited to lead the consumer business once GSK completes its planned split. ($1 = 0.7215 pounds)

GSK pursuing split as easing of COVID curbs aids earnings
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email